JP2011522874A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522874A5 JP2011522874A5 JP2011513069A JP2011513069A JP2011522874A5 JP 2011522874 A5 JP2011522874 A5 JP 2011522874A5 JP 2011513069 A JP2011513069 A JP 2011513069A JP 2011513069 A JP2011513069 A JP 2011513069A JP 2011522874 A5 JP2011522874 A5 JP 2011522874A5
- Authority
- JP
- Japan
- Prior art keywords
- influenza
- virus
- virus strain
- vaccine
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000712431 Influenza A virus Species 0.000 claims description 86
- 239000000427 antigen Substances 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 58
- 108091007433 antigens Proteins 0.000 claims description 58
- 206010064097 avian influenza Diseases 0.000 claims description 46
- 206010069767 H1N1 influenza Diseases 0.000 claims description 41
- 201000010740 swine influenza Diseases 0.000 claims description 41
- 241000713196 Influenza B virus Species 0.000 claims description 39
- 229960003971 influenza vaccine Drugs 0.000 claims description 38
- 229940124873 Influenza virus vaccine Drugs 0.000 claims description 19
- 239000002671 adjuvant Substances 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 8
- 239000007764 o/w emulsion Substances 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 7
- 101710154606 Hemagglutinin Proteins 0.000 claims description 6
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 6
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 6
- 101710176177 Protein A56 Proteins 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 239000000185 hemagglutinin Substances 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 4
- 235000013601 eggs Nutrition 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 241000271566 Aves Species 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 108010058846 Ovalbumin Proteins 0.000 claims description 2
- 108010064983 Ovomucin Proteins 0.000 claims description 2
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims description 2
- 239000005388 borosilicate glass Substances 0.000 claims description 2
- 230000035931 haemagglutination Effects 0.000 claims description 2
- 229940092253 ovalbumin Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 229940117432 influenza b virus antigen Drugs 0.000 claims 2
- 238000002255 vaccination Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 208000037797 influenza A Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13191808P | 2008-06-12 | 2008-06-12 | |
| US61/131,918 | 2008-06-12 | ||
| GBGB0905570.8A GB0905570D0 (en) | 2009-03-31 | 2009-03-31 | Combined vaccines |
| GB0905570.8 | 2009-03-31 | ||
| PCT/IB2009/006038 WO2009150532A1 (en) | 2008-06-12 | 2009-06-12 | Combined influenza vaccines for seasonal and pandemic protection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011522874A JP2011522874A (ja) | 2011-08-04 |
| JP2011522874A5 true JP2011522874A5 (enExample) | 2012-07-19 |
Family
ID=40672059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513069A Pending JP2011522874A (ja) | 2008-06-12 | 2009-06-12 | 季節性および汎流行性の防御のための混合インフルエンザワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20110200635A1 (enExample) |
| EP (1) | EP2303321A1 (enExample) |
| JP (1) | JP2011522874A (enExample) |
| KR (1) | KR20110019417A (enExample) |
| CN (1) | CN102245203A (enExample) |
| AU (1) | AU2009259006A1 (enExample) |
| CA (1) | CA2727322A1 (enExample) |
| GB (1) | GB0905570D0 (enExample) |
| WO (1) | WO2009150532A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010060430A2 (en) * | 2008-11-28 | 2010-06-03 | Statens Serum Institut | Optimized influenza vaccines |
| AU2015203072B2 (en) * | 2009-02-10 | 2017-05-25 | Seqirus UK Limited | Influenza vaccine regimens for pandemic-associated strains |
| EP2396030B1 (en) | 2009-02-10 | 2015-08-12 | Novartis AG | Influenza vaccine regimens for pandemic-associated strains |
| US9051359B2 (en) | 2009-03-30 | 2015-06-09 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
| JP2012525370A (ja) * | 2009-04-27 | 2012-10-22 | ノバルティス アーゲー | インフルエンザに対して防御するためのアジュバント添加ワクチン |
| US8673314B2 (en) | 2009-05-26 | 2014-03-18 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| WO2011044152A1 (en) * | 2009-10-05 | 2011-04-14 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer | Protection against pandemic and seasonal strains of influenza |
| WO2011103453A2 (en) | 2010-02-18 | 2011-08-25 | Mount Sinai School Of Medicine | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| US9708373B2 (en) | 2010-03-30 | 2017-07-18 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccine and uses thereof |
| JP5884100B2 (ja) * | 2011-08-31 | 2016-03-15 | 公益財団法人東京都医学総合研究所 | 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有するＤＩｓ株由来組換えワクシニアウイルス |
| WO2013043729A1 (en) | 2011-09-20 | 2013-03-28 | Mount Sinai School Of Medicine | Influenza virus vaccines and uses thereof |
| JP5918870B2 (ja) * | 2012-03-06 | 2016-05-18 | クルセル ホランド ベー ヴェー | インフルエンザに対する改善されたワクチン接種 |
| US9700614B2 (en) | 2012-12-17 | 2017-07-11 | Eurocine Vaccines Ab | Intranasal vaccination dosage regimen |
| EP2934581B1 (en) | 2012-12-18 | 2022-09-14 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| JP2016534070A (ja) * | 2013-10-25 | 2016-11-04 | ロイコケア・アクチェンゲゼルシャフト | 安定化ワクチンの製造のための新規方法 |
| CA2970163A1 (en) | 2014-12-19 | 2016-06-23 | Oregon Health & Science University | Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
| WO2016104584A1 (ja) * | 2014-12-25 | 2016-06-30 | 第一三共株式会社 | 皮内投与インフルエンザワクチン組成物 |
| AU2016209032A1 (en) | 2015-01-23 | 2017-08-10 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| WO2016207853A2 (en) | 2015-06-26 | 2016-12-29 | Seqirus UK Limited | Antigenically matched influenza vaccines |
| EP3471767A4 (en) | 2016-06-15 | 2020-01-15 | Icahn School of Medicine at Mount Sinai | Influenza virus hemagglutinin proteins and uses thereof |
| CN107151659B (zh) * | 2017-03-01 | 2021-04-02 | 苏州系统医学研究所 | 一种流感病毒株及其应用 |
| EP3606555A4 (en) | 2017-04-07 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| WO2019143955A1 (en) * | 2018-01-22 | 2019-07-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly protective inactivated influenza virus vaccine |
| EP3810634A4 (en) | 2018-06-21 | 2022-07-27 | Icahn School of Medicine at Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1645283A1 (en) * | 2004-10-08 | 2006-04-12 | Chiron Behring GmbH & Co. KG | Combination vaccine |
| AR053833A1 (es) * | 2005-03-23 | 2007-05-23 | Glaxosmithkline Biolog Sa | Composicion inmunogenetica |
| WO2007052060A1 (en) * | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines extemporaneously adsorbed to aluminium adjuvants |
| JP2009514850A (ja) * | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン |
| SI2032163T1 (sl) * | 2006-06-15 | 2013-05-31 | Novartis Ag | Večodmerni režim za ceplenje proti influenci, pri katerem se privarčuje adjuvant |
| EP2066345B1 (en) * | 2006-09-11 | 2015-02-25 | Novartis AG | Making influenza virus vaccines without using eggs |
| EP2532362A1 (en) * | 2006-12-06 | 2012-12-12 | Novartis AG | Vaccines including antigen from four strains of influenza virus |
| JP5305427B2 (ja) * | 2007-01-11 | 2013-10-02 | 公立大学法人大阪府立大学 | インフルエンザウイルスに対する抗体の産生方法 |
| TWI403518B (zh) * | 2007-01-23 | 2013-08-01 | Academia Sinica | 一種流感疫苗及其使用方法 |
| GB0810305D0 (en) * | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| WO2009071633A1 (en) * | 2007-12-06 | 2009-06-11 | Glaxosmithkline Biologicals S.A. | Influenza composition |
| US20110014230A1 (en) * | 2008-03-18 | 2011-01-20 | Novartis Ag | preparation of influenza virus vaccine antigens |
-
2009
- 2009-03-31 GB GBGB0905570.8A patent/GB0905570D0/en not_active Ceased
- 2009-06-12 CN CN2009801230987A patent/CN102245203A/zh active Pending
- 2009-06-12 JP JP2011513069A patent/JP2011522874A/ja active Pending
- 2009-06-12 WO PCT/IB2009/006038 patent/WO2009150532A1/en not_active Ceased
- 2009-06-12 AU AU2009259006A patent/AU2009259006A1/en not_active Abandoned
- 2009-06-12 US US12/997,577 patent/US20110200635A1/en not_active Abandoned
- 2009-06-12 KR KR1020117000394A patent/KR20110019417A/ko not_active Ceased
- 2009-06-12 CA CA2727322A patent/CA2727322A1/en not_active Abandoned
- 2009-06-12 EP EP09762060A patent/EP2303321A1/en not_active Withdrawn
-
2014
- 2014-08-18 US US14/461,852 patent/US20140363468A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011522874A5 (enExample) | ||
| Becker et al. | Influenza vaccines: successes and continuing challenges | |
| Vasou et al. | Targeting pattern recognition receptors (PRR) for vaccine adjuvantation: from synthetic PRR agonists to the potential of defective interfering particles of viruses | |
| Kumar et al. | Novel platforms for the development of a universal influenza vaccine | |
| Cappellano et al. | Nano-microparticle platforms in developing next-generation vaccines | |
| Atsmon et al. | Priming by a novel universal influenza vaccine (Multimeric-001)—A gateway for improving immune response in the elderly population | |
| Sekiya et al. | Selecting and using the appropriate influenza vaccine for each individual | |
| Zhang et al. | Universal influenza vaccines, a dream to be realized soon | |
| Cargnin Faccin et al. | Pandemic preparedness through vaccine development for avian influenza viruses | |
| JP6185548B2 (ja) | インフルエンザワクチンの製造方法 | |
| Sebastian et al. | Clinical advances in viral-vectored influenza vaccines | |
| Vemula et al. | Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness | |
| Li et al. | Adjuvantation of influenza vaccines to induce cross-protective immunity | |
| Clegg et al. | Clinical vaccine development for H5N1 influenza | |
| Budimir et al. | Heterosubtypic cross‐protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration | |
| ES2469568T3 (es) | Vacuna contra la gripe | |
| Quan et al. | Progress in the development of virus-like particle vaccines against respiratory viruses | |
| Trucchi et al. | Universal influenza virus vaccines: what needs to happen next? | |
| Hatz et al. | A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects | |
| El Sahly et al. | Pandemic H5N1 influenza vaccine development: an update | |
| Deans et al. | Influenza vaccines provide diminished protection but are cost‐saving in older adults | |
| Esposito et al. | Preventing influenza in younger children | |
| Chu et al. | Respiratory viruses and virus-like particle vaccine development: how far have we advanced? | |
| EP2822585B1 (en) | Improved vaccination against influenza | |
| Mokalla et al. | Influenza vaccines: current status, adjuvant strategies, and efficacy |